期刊文献+

在二溴氨茴酸甲酯戊二睛过敏患者中进行定量斑贴试验及重复暴露外用试验

Quantitative patch and repeated open application testing in methyldibromo glutaronitrile- sensitive patients
下载PDF
导出
摘要 Contact allergy to methyldibromo glutaronitrile (MDBGN), often combined with phenoxyethanol (PE)(e.g., Euxyl K 400.), increased throughout the 1990s in Europe. Consequently, in 2003, the European Commission banned its use in leave- on products, where its use concentration was considered too high and the non- sensitizing use concentration as yet unknown. The 2 objectives of the study are(a) to find amaximum non- eliciting concentration in a leave- on product in MDBGN/PE- sensitized patients,which could possibly also be considered safe regarding induction and (b) to find the best patch test concentration for MDBGN.We,therefore,performedause- relatedtest(ROAT)in patients sensitized to MDBGN/PE (n=39) with 3 concentrations of MDBGN/PE (50, 100 and 250 p.p.m. MDBGN, respectively). A subset of these patients (n=24) was later patch- tested with various concentrations (0.1, 0.2, 0.3 and 0.5% MDBGN, respectively). 15 patients (38% , 95% confidence interval (CI)=23- 55% ) had a negative and 24 (62% ; 95% CI=45- 77% ) a positive overall repeated open application test (ROAT) result. 13 reacted to the lowest (50 p.p.m.), 8 to the middle (100 p.p.m.) and 3 to the highest concentration (250 p.p.m.) only. In those 13 reacting to the lowest ROAT concentration, dermatitis developed within a few days (1- 7). The strength of the initial and the confirmatory patch test result, respectively, and the outcome of the ROAT were positively associated. Of the 24 patients with a use and confirmatory patch test, 15 reacted to 0.1% MDBGN, 16 to 0.2% , 17 to 0.3% and 22 to 0.5% . With the patch test concentration of 0.5% , the number of ROAT- negative patients but patch- test- positive patients increases considerably, particularly due to + reactions. A maximum sensitivity of 94% (95% CI=70- 100% ) is reached with a patch test concentration of 0.2% , and is not further improved by increasing the concentration. However, the specificity decreases dramatically from 88 (95% CI=47- 100% ) with 0.2% to a mere 12.5% (95% CI=0- 53% ) with 0.5% . It can be concluded (a) that for MDBGN 0.2% is very likely the best patch test concentration and (b) that 50 p.p.m. in a leave- on product can elicit contact dermatitis in sensitized persons. We were, therefore, unable to find a safe, still microbicidal, concentration for leave- on products. By contrast, with other contact allergens, dose- response use tests may be able to identify a non- eliciting concentration, which could give valuable clues to a non- inducing (i.e., safe) concentration in products. Contact allergy to methyldibromo glutaronitrile (MDBGN), often combined with phenoxyethanol (PE)(e.g., Euxyl K 400.), increased throughout the 1990s in Europe. Consequently, in 2003, the European Commission banned its use in leave- on products, where its use concentration was considered too high and the non- sensitizing use concentration as yet unknown. The 2 objectives of the study are(a) to find amaximum non- eliciting concentration in a leave- on product in MDBGN/PE- sensitized patients,which could possibly also be considered safe regarding induction and (b) to find the best patch test concentration for MDBGN.We,therefore,performedause- relatedtest(ROAT)in patients sensitized to MDBGN/PE (n=39) with 3 concentrations of MDBGN/PE (50, 100 and 250 p.p.m. MDBGN, respectively). A subset of these patients (n=24) was later patch- tested with various concentrations (0.1, 0.2, 0.3 and 0.5% MDBGN, respectively). 15 patients (38% , 95% confidence interval (CI)=23- 55% ) had a negative and 24 (62% ; 95% CI=45- 77% ) a positive overall repeated open application test (ROAT) result. 13 reacted to the lowest (50 p.p.m.), 8 to the middle (100 p.p.m.) and 3 to the highest concentration (250 p.p.m.) only. In those 13 reacting to the lowest ROAT concentration, dermatitis developed within a few days (1- 7). The strength of the initial and the confirmatory patch test result, respectively, and the outcome of the ROAT were positively associated. Of the 24 patients with a use and confirmatory patch test, 15 reacted to 0.1% MDBGN, 16 to 0.2% , 17 to 0.3% and 22 to 0.5% . With the patch test concentration of 0.5% , the number of ROAT- negative patients but patch- test- positive patients increases considerably, particularly due to + reactions. A maximum sensitivity of 94% (95% CI=70- 100% ) is reached with a patch test concentration of 0.2% , and is not further improved by increasing the concentration. However, the specificity decreases dramatically from 88 (95% CI=47- 100% ) with 0.2% to a mere 12.5% (95% CI=0- 53% ) with 0.5% . It can be concluded (a) that for MDBGN 0.2% is very likely the best patch test concentration and (b) that 50 p.p.m. in a leave- on product can elicit contact dermatitis in sensitized persons. We were, therefore, unable to find a safe, still microbicidal, concentration for leave- on products. By contrast, with other contact allergens, dose- response use tests may be able to identify a non- eliciting concentration, which could give valuable clues to a non- inducing (i.e., safe) concentration in products.
机构地区 IVDK- Zentrale
出处 《世界核心医学期刊文摘(皮肤病学分册)》 2005年第8期60-61,共2页 Digest of the World Core Medical JOurnals:Dermatology
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部